Spots Global Cancer Trial Database for echocardiography

Every month we try and update this database with for echocardiography cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)	NCT05564403	Recurrent Bilia... Recurrent Dista... Recurrent Gallb... Recurrent Intra... Stage III Dista... Stage III Hilar... Stage III Intra... Stage IV Distal... Stage IV Hilar ... Stage IV Intrah... Unresectable Bi... Unresectable Di... Unresectable Ga... Unresectable In...	Binimetinib Biopsy Biospecimen Col... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Leucovorin Calc... Magnetic Resona... Multigated Acqu... Oxaliplatin	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	NCT01116648	Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Ovarian Serous ... Ovarian Serous ... Primary Periton... Triple-Negative...	Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer	NCT03939897	Anatomic Stage ... Metastatic Brea... Metastatic HER2... Metastatic Horm... Recurrent Breas...	Abemaciclib Biopsy Biospecimen Col... Copanlisib Hydr... Diagnostic Imag... Echocardiograph... Fulvestrant Multigated Acqu...	18 Years -	National Cancer Institute (NCI)
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)	NCT06210750	T Acute Lymphob... T Lymphoblastic...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Calaspargase Pe... Computed Tomogr... Cyclophosphamid... Cytarabine Daunorubicin Dexamethasone Doxorubicin Echocardiograph... Lumbar Puncture Mercaptopurine Methotrexate Multigated Acqu... Navitoclax Nelarabine Pegaspargase Positron Emissi... Thioguanine Venetoclax Vincristine X-Ray Imaging	18 Years - 60 Years	National Cancer Institute (NCI)
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer	NCT03811015	Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag...	Biospecimen Col... Cisplatin Computed Tomogr... Echocardiograph... Fludeoxyglucose... Intensity-Modul... Nivolumab Patient Observa... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma	NCT06242834	B-Cell Non-Hodg...	Biospecimen Col... Computed Tomogr... Echocardiograph... Pembrolizumab Positron Emissi... Tazemetostat	18 Years -	Northwestern University
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma	NCT05359211	Recurrent Diffu... Recurrent Diffu... Recurrent Grade... Recurrent Prima... Refractory Diff... Refractory Diff... Refractory Grad... Refractory Prim... Transformed Ind...	Cyclophosphamid... Fludarabine Lisocabtagene M... Polymer-conjuga... X-Ray Imaging Echocardiograph... Multigated Acqu... Bone Marrow Bio... Bone Marrow Asp... Lumbar Puncture Computed Tomogr... Positron Emissi... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02446600	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima...	Biospecimen Col... Carboplatin Cediranib Malea... Computed Tomogr... Echocardiograph... Gemcitabine Gemcitabine Hyd... Laboratory Biom... Magnetic Resona... Multigated Acqu... Olaparib Paclitaxel Pegylated Lipos... Pharmacological... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ	NCT04144023	Breast Ductal C...	Granulocyte-Mac... Multi-epitope H... Therapeutic Con... Echocardiograph... Biospecimen Col... Biopsy	18 Years -	Mayo Clinic
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer	NCT06287775	Extensive Stage... Stage IV Lung C...	Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Durvalumab Echocardiograph... Iadademstat Magnetic Resona... Multigated Acqu...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma	NCT06232044	Recurrent Multi... Refractory Mult...	Iberdomide Belantamab Mafo... Dexamethasone Echocardiograph... Computed Tomogr... Magnetic Resona... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col...	18 Years -	Alliance for Clinical Trials in Oncology
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	NCT02496208	Bladder Small C... Bladder Squamou... Bladder Urothel... Clear Cell Rena... Invasive Bladde... Invasive Bladde... Invasive Sarcom... Kidney Medullar... Malignant Genit... Malignant Solid... Penile Carcinom... Penile Squamous... Renal Cell Carc... Renal Pelvis Ur... Sarcomatoid Ren... Stage III Bladd... Stage III Penil... Stage III Renal... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines	NCT03155802	Cardiotoxicity Heart Failure Breast Cancer Anthracycline I... Biomarkers Echocardiograph...		18 Years - 85 Years	Stony Brook University
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial	NCT02275533	Acute Myeloid L...	Biospecimen Col... Bone Marrow Bio... Clinical Observ... Echocardiograph... Nivolumab	18 Years -	National Cancer Institute (NCI)
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma	NCT03604978	Grade 2 Meningi... Grade 3 Meningi... Recurrent Menin...	Biospecimen Col... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab Stereotactic Ra...	18 Years -	National Cancer Institute (NCI)
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer	NCT04181060	Advanced Lung N... Metastatic Lung... Recurrent Lung ... Stage IIIB Lung... Stage IV Lung C...	Bevacizumab Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Osimertinib	18 Years -	National Cancer Institute (NCI)
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases	NCT06013423	Acute Leukemia ... Acute Lymphobla... Acute Myeloid L... Blastic Plasmac... Hematopoietic a... Mixed Phenotype... Myelodysplastic... Myeloproliferat... Non-Hodgkin Lym... Chronic Myeloid...	Biospecimen Col... Bone Marrow Asp... Cyclophosphamid... Cyclosporine Diagnostic Imag... Echocardiograph... Fludarabine Pho... Multigated Acqu... Mycophenolate M... Survey Administ... Thiotepa Total-Body Irra... Umbilical Cord ...	6 Months - 65 Years	Fred Hutchinson Cancer Center
Gilteritinib for the Treatment of ALK NSCLC	NCT06225427	Lung Non-Small ... Stage IV Lung C...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Gilteritinib Magnetic Resona... Questionnaire A...	18 Years -	University of Michigan Rogel Cancer Center
Strain Imaging in Breast Cancer Patients Receiving Trastuzumab	NCT02080390	Her 2 Positive ...	Transthoracic e...	18 Years -	University of Florida
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)	NCT03970096	Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col...	1 Year - 60 Years	Fred Hutchinson Cancer Center
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)	NCT06357988	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Echocardiograph... Radionuclide Im... Vismodegib	18 Years -	National Cancer Institute (NCI)
Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients	NCT00806507	Breast Cancer	Echocardiograms Blood Test	18 Years -	M.D. Anderson Cancer Center
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial	NCT02275533	Acute Myeloid L...	Biospecimen Col... Bone Marrow Bio... Clinical Observ... Echocardiograph... Nivolumab	18 Years -	National Cancer Institute (NCI)
A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia	NCT05761171	Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Mixe...	Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cytarabine Echocardiograph... Fludarabine Pho... Hydrocortisone ... Lumbar Puncture Methotrexate Multigated Acqu... Prednisolone Prednisone Revumenib Vincristine Sul...	1 Month - 6 Years	Children's Oncology Group
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer	NCT04092270	Endometrial Hig... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... FIGO Grade 1 En... FIGO Grade 2 En... Ovarian High Gr... Ovarian Seromuc... Ovarian Undiffe... Platinum-Sensit... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Low G... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima...	Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Pegylated Lipos... Peposertib	18 Years -	National Cancer Institute (NCI)
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	NCT01989585	Clinical Stage ... Clinical Stage ... Malignant Solid... Metastatic Mela... Unresectable Me...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Echocardiograph... Laboratory Biom... Magnetic Resona... Multigated Acqu... Navitoclax Pharmacological... Trametinib	18 Years -	National Cancer Institute (NCI)
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma	NCT06151847	Clinical Stage ... Metastatic Mela... Pathologic Stag... Unresectable Me...	Biospecimen Col... Cyclophosphamid... Echocardiograph... Fludarabine Interleukin-2 Lifileucel Magnetic Resona... Multigated Acqu... Tumor Resection	18 Years - 70 Years	University of Kansas Medical Center
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	NCT05936229	Recurrent B Acu... Recurrent B-Cel... Refractory B Ac... Refractory B-Ce... Recurrent Mantl... Refractory Mant...	Interferon Beta... X-Ray Imaging Echocardiograph... Multigated Acqu... Computed Tomogr... Positron Emissi... Lumbar Puncture Bone Marrow Asp... Bone Marrow Bio... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative	NCT04929041	Lung Adenocarci... Lung Adenosquam... Lung Non-Small ... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab Positron Emissi... Quality-of-Life... Stereotactic Bo...	18 Years -	National Cancer Institute (NCI)
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor	NCT00352534	Stage I Kidney ... Stage II Kidney... Stage III Kidne...	3-Dimensional C... Biospecimen Col... Chest Radiograp... Computed Tomogr... Dactinomycin Doxorubicin Hyd... Echocardiograph... Magnetic Resona... Therapeutic Con... Ultrasound Imag... Vincristine Sul...	- 29 Years	Children's Oncology Group
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis	NCT06022939	AL Amyloidosis	Autologous Hema... Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bortezomib Computed Tomogr... Cyclophosphamid... Daratumumab and... Dexamethasone Echocardiograph... Magnetic Resona... Melphalan Positron Emissi... Stem Cell Isola... Survey Administ...	18 Years -	SWOG Cancer Research Network
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer	NCT02345265	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Carcino... Ovarian High Gr... Ovarian High Gr... Primary Periton... Primary Periton... Primary Periton...	Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib Questionnaire A...	18 Years -	National Cancer Institute (NCI)
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas	NCT06422806	Stage III Soft ... Stage IV Soft T... Undifferentiate...	Biospecimen Col... Diagnostic Imag... Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab	18 Years -	National Cancer Institute (NCI)
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	NCT02496208	Bladder Small C... Bladder Squamou... Bladder Urothel... Clear Cell Rena... Invasive Bladde... Invasive Bladde... Invasive Sarcom... Kidney Medullar... Malignant Genit... Malignant Solid... Penile Carcinom... Penile Squamous... Renal Cell Carc... Renal Pelvis Ur... Sarcomatoid Ren... Stage III Bladd... Stage III Penil... Stage III Renal... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)	NCT03907475	Malignant Solid...	Biopsy Biospecimen Col... Capecitabine Carboplatin Computed Tomogr... Durvalumab Echocardiograph... Gemcitabine Hyd... Nab-paclitaxel Paclitaxel Pegylated Lipos...	18 Years -	National Cancer Institute (NCI)
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression	NCT02555189	Castration-Resi... Metastatic Pros... Prostate Carcin... Stage IV Prosta...	Enzalutamide Ribociclib Laboratory Biom... Pharmacological... Biospecimen Col... Biopsy Echocardiograph... Multigated Acqu... Bone Scan Computed Tomogr... Magnetic Resona...	18 Years -	Thomas Jefferson University
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)	NCT02595944	Stage IB Lung N... Stage II Lung N... Stage IIIA Lung...	Biospecimen Col... Computed Tomogr... Echocardiograph... Nivolumab Observation Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)	NCT02194738	Stage IB Lung N... Stage II Lung N... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Lung...	Biospecimen Col... Carboplatin Cisplatin Clinical Observ... Computed Tomogr... Crizotinib Cytology Specim... Echocardiograph... Erlotinib Gemcitabine Hyd... Nivolumab Paclitaxel Pembrolizumab Pemetrexed Pemetrexed Diso... Placebo Adminis... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma	NCT04609046	Primary Diffuse...	Bone Marrow Asp... Computed Tomogr... Echocardiograph... Lenalidomide Lumbar Puncture Magnetic Resona... Methotrexate Nivolumab Positron Emissi... Rituximab Ultrasound Imag...	18 Years -	National Cancer Institute (NCI)
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)	NCT06390826	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... Sunitinib	18 Years -	National Cancer Institute (NCI)
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors	NCT01841736	Foregut Neuroen... Hindgut Neuroen... Metastatic Dige... Metastatic Neur... Midgut Neuroend... Neuroendocrine ... Recurrent Diges... Regional Digest...	Biospecimen Col... Computed Tomogr... Echocardiograph... Laboratory Biom... Magnetic Resona... Multigated Acqu... Pazopanib Hydro... Placebo Adminis... Quality-of-Life... X-Ray Imaging	18 Years -	National Cancer Institute (NCI)
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis	NCT04370301	Primary Myelofi... Secondary Myelo...	Cyclophosphamid... JAK Inhibitor Fludarabine Recombinant Gra... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra... Computed Tomogr... Magnetic Resona... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... Echocardiograph... Multigated Acqu...	18 Years -	Fred Hutchinson Cancer Center
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	NCT05564377	Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma...	Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib	-	National Cancer Institute (NCI)
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)	NCT06400225	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... Ulixertinib	18 Years -	National Cancer Institute (NCI)
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis	NCT06022939	AL Amyloidosis	Autologous Hema... Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bortezomib Computed Tomogr... Cyclophosphamid... Daratumumab and... Dexamethasone Echocardiograph... Magnetic Resona... Melphalan Positron Emissi... Stem Cell Isola... Survey Administ...	18 Years -	SWOG Cancer Research Network
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)	NCT06126276	Malignant Femal... Malignant Solid... Recurrent Malig... Recurrent Malig...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Neratinib Malea... Palbociclib	18 Years -	National Cancer Institute (NCI)
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas	NCT06422806	Stage III Soft ... Stage IV Soft T... Undifferentiate...	Biospecimen Col... Diagnostic Imag... Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab	18 Years -	National Cancer Institute (NCI)
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma	NCT05950113	Recurrent Multi... Refractory Mult...	Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Echocardiograph... Fludarabine Fludeoxyglucose... Immunotherapy Leukapheresis Magnetic Resona... Positron Emissi...	18 Years - 74 Years	Jonsson Comprehensive Cancer Center
Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG	NCT04892667	Lymphoma, Non-H... Lymphoma, Hodgk...	intervention	18 Years -	Assistance Publique - Hôpitaux de Paris
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis	NCT06022939	AL Amyloidosis	Autologous Hema... Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bortezomib Computed Tomogr... Cyclophosphamid... Daratumumab and... Dexamethasone Echocardiograph... Magnetic Resona... Melphalan Positron Emissi... Stem Cell Isola... Survey Administ...	18 Years -	SWOG Cancer Research Network
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma	NCT06249191	Diffuse Large B... High Grade B-Ce...	Biopsy Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Cyclophosphamid... Doxorubicin Echocardiograph... Etoposide Magnetic Resona... Mosunetuzumab Multigated Acqu... Positron Emissi... Prednisone Vincristine	18 Years - 75 Years	OHSU Knight Cancer Institute
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers	NCT05691504	Advanced Endome... Metastatic Endo... Metastatic Fall... Metastatic Plat... Metastatic Prim... Recurrent Endom... Recurrent Fallo... Recurrent Plati... Recurrent Prima... Stage III Uteri... Stage IV Uterin...	Biopsy Biospecimen Col... Cobimetinib Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Pelcitoclax	18 Years -	National Cancer Institute (NCI)
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations	NCT06043713	Metastatic Colo... Metastatic Lung... Metastatic Panc... Stage IV Colore... Stage IV Lung C... Stage IV Pancre...	Bendamustine Biopsy Biospecimen Col... Computed Tomogr... Cyclophosphamid... Echocardiograph... Fludarabine Leukapheresis Magnetic Resona... Multigated Acqu... Positron Emissi... T-cell Receptor...	18 Years -	Fred Hutchinson Cancer Center
Cancer Therapy Effects on the Heart	NCT04262830	Cardiotoxicity Pediatric Cance... Heart Failure	Cardiac magneti... Echocardiograph... Electrocardiogr...	13 Years - 39 Years	University of California, San Diego
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma	NCT05359211	Recurrent Diffu... Recurrent Diffu... Recurrent Grade... Recurrent Prima... Refractory Diff... Refractory Diff... Refractory Grad... Refractory Prim... Transformed Ind...	Cyclophosphamid... Fludarabine Lisocabtagene M... Polymer-conjuga... X-Ray Imaging Echocardiograph... Multigated Acqu... Bone Marrow Bio... Bone Marrow Asp... Lumbar Puncture Computed Tomogr... Positron Emissi... Biospecimen Col... Biopsy	18 Years -	Fred Hutchinson Cancer Center
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)	NCT06400225	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... Ulixertinib	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	NCT00557193	Acute Lymphobla... Acute Undiffere... Childhood T Acu...	Asparaginase Biospecimen Col... Bone Marrow Bio... Cyclophosphamid... Cytarabine Daunorubicin Hy... Dexamethasone Echocardiograph... Etoposide Filgrastim Laboratory Biom... Lestaurtinib Leucovorin Calc... Mercaptopurine Methotrexate Methylprednisol... Multigated Acqu... Pegaspargase Pharmacological... Prednisone Therapeutic Hyd... Vincristine Sul...	- 1 Year	Children's Oncology Group
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome	NCT06287944	Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Actinium Ac 225... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Daratumumab Echocardiograph... Fludarabine Hematopoietic C... Indium In 111-D... Melphalan Multigated Acqu... Radionuclide Im... Single Photon E... Sirolimus Tacrolimus Total Marrow an...	18 Years -	City of Hope Medical Center
Anthracycline Induced Cardiotoxicity - Early Detection by Combination of Diastolic Strain and T2-mapping	NCT03940625	Breast Cancer Myocardial Dama... Cardiotoxicity	Cardiac MRI and...	18 Years -	Heinrich-Heine University, Duesseldorf
Stress Echocardiography to Identify Chemotherapy Induced Cardiotoxicity in Cancer Patients With Heart Failure Risk	NCT05950399	Hematopoietic a... Malignant Solid...	Echocardiograph... Electronic Heal... Questionnaire A... Stress Echocard...	18 Years -	Mayo Clinic
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial	NCT05554328	Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Biopsy Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Echocardiograph... Multigated Acqu... Olaparib Selumetinib Sul...	18 Years -	National Cancer Institute (NCI)
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia	NCT04214249	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Secondary Acute...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cytarabine Daunorubicin Hy... Echocardiograph... Hematopoietic C... Idarubicin Hydr... Multigated Acqu... Pembrolizumab Punch Biopsy	18 Years - 75 Years	National Cancer Institute (NCI)
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery	NCT01947023	Metastatic Thyr... Unresectable Th...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Dabrafenib Mesy... Echocardiograph... Lapatinib Lapatinib Ditos... Magnetic Resona... Multigated Acqu... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin	NCT02423356	Breast Neoplasm... Lymphoma Sarcoma	Echocardiogram	18 Years -	Indiana University
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia	NCT03418038	Clonal Cytopeni... High Grade B-Ce... Recurrent Diffu... Recurrent Hodgk... Recurrent Lymph... Refractory Diff... Refractory Lymp... Chronic Myelomo...	Ascorbic Acid Carboplatin Cisplatin Cytarabine Dexamethasone Etoposide Gemcitabine Hyd... Ifosfamide Laboratory Biom... Oxaliplatin Placebo Adminis... Questionnaire A... Rituximab Decitabine Biospecimen Col... Core Biopsy Bone Marrow Asp... Bone Marrow Bio... Echocardiograph... Positron Emissi... Magnetic Resona... Central Venous ... Portacath Place... Computed Tomogr...	18 Years -	Mayo Clinic
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery	NCT04195399	Desmoid Fibroma... Recurrent Desmo... Unresectable De...	Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Nirogacestat Quality-of-Life... Questionnaire A... X-Ray Imaging	12 Months - 18 Years	Children's Oncology Group
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)	NCT06400264	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Nivolumab Relatlimab	18 Years -	National Cancer Institute (NCI)
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma	NCT03031730	Plasmacytoma Recurrent Multi... Refractory Mult...	Biospecimen Col... Bone Marrow Asp... Carfilzomib Dexamethasone Dexamethasone S... Echocardiograph... Lenalidomide Navtemadlin	18 Years -	National Cancer Institute (NCI)
A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)	NCT06124157	B Acute Lymphob...	Biospecimen Col... Blinatumomab Bone Marrow Bio... Calaspargase Pe... Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Doxorubicin Echocardiograph... Leucovorin Mercaptopurine Methotrexate Multigated Acqu... Pegaspargase Prednisolone Prednisone Radiation Thera... Thioguanine Vincristine	366 Days - 46 Years	National Cancer Institute (NCI)
Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG	NCT04892667	Lymphoma, Non-H... Lymphoma, Hodgk...	intervention	18 Years -	Assistance Publique - Hôpitaux de Paris
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma	NCT06164275	Classic Hodgkin...	Biopsy Biospecimen Col... Computed Tomogr... Dacarbazine Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab Positron Emissi... Vinblastine	18 Years -	Northwestern University
Exercise Response After Revalidation in Cancer Patients	NCT04461392	Oncology Cardiac Toxicit...	Cardiorespirato...	18 Years - 90 Years	Universitair Ziekenhuis Brussel
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma	NCT06164275	Classic Hodgkin...	Biopsy Biospecimen Col... Computed Tomogr... Dacarbazine Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab Positron Emissi... Vinblastine	18 Years -	Northwestern University
Comparing N-terminal-proB-type Natriuretic Peptide With Other Criteria in Pleural Fluid Analysis	NCT05797649	Pleural Effusio... Heart Failure Malignant Neopl... Fluid Overload Hypoalbuminemia Renal Failure Cirrhosis Infections		18 Years -	Chinese University of Hong Kong
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma	NCT02339571	Stage III Cutan... Stage IV Cutane...	Biospecimen Col... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Multigated Acqu... Nivolumab Sargramostim	18 Years -	National Cancer Institute (NCI)
A Study Using a New Drug, Nivolumab, in Combination With Chemotherapy Drugs to Treat a Type of Cancer Called Nasopharyngeal Carcinoma (NPC)	NCT06064097	Stage II Nasoph... Stage III Nasop... Stage IV Nasoph...	Biopsy Biospecimen Col... Chest Radiograp... Cisplatin Computed Tomogr... Echocardiograph... Electronic Heal... Fluciclovine F1... Gemcitabine Magnetic Resona... Multigated Acqu... Nivolumab Positron Emissi... Quality-of-Life... Questionnaire A... Radiation Thera... X-Ray Imaging	- 21 Years	National Cancer Institute (NCI)
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression	NCT02555189	Castration-Resi... Metastatic Pros... Prostate Carcin... Stage IV Prosta...	Enzalutamide Ribociclib Laboratory Biom... Pharmacological... Biospecimen Col... Biopsy Echocardiograph... Multigated Acqu... Bone Scan Computed Tomogr... Magnetic Resona...	18 Years -	Thomas Jefferson University
Cardiovascular Function in Adult Survivors of Childhood Malignancies	NCT01415999	Childhood Cance...		18 Years - 35 Years	The University of Hong Kong
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	NCT01116648	Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Ovarian Serous ... Ovarian Serous ... Primary Periton... Triple-Negative...	Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
Cardiovascular Function in Adult Survivors of Childhood Malignancies	NCT01415999	Childhood Cance...		18 Years - 35 Years	The University of Hong Kong

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: